Journal of Clinical Virology
Volume 47, Issue 1 , Pages 76-78 , January 2010

Sustained virological response in a patient with chronic hepatitis C treated by monotherapy with the NS3-4A protease inhibitor telaprevir

  • Fumitaka Suzuki

      Affiliations

    • Department of Hepatology, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo 105-8470, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 44 877 5111; fax: +81 44 860 1623.
    • ,
  • Yoshiyuki Suzuki

      Affiliations

    • Department of Hepatology, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo 105-8470, Japan
    • ,
  • Norio Akuta

      Affiliations

    • Department of Hepatology, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo 105-8470, Japan
    • ,
  • Hitomi Sezaki

      Affiliations

    • Department of Hepatology, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo 105-8470, Japan
    • ,
  • Hiromi Yatsuji

      Affiliations

    • Department of Hepatology, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo 105-8470, Japan
    • ,
  • Yasuji Arase

      Affiliations

    • Department of Hepatology, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo 105-8470, Japan
    • ,
  • Miharu Hirakawa

      Affiliations

    • Department of Hepatology, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo 105-8470, Japan
    • ,
  • Yusuke Kawamura

      Affiliations

    • Department of Hepatology, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo 105-8470, Japan
    • ,
  • Tetsuya Hosaka

      Affiliations

    • Department of Hepatology, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo 105-8470, Japan
    • ,
  • Masahiro Kobayashi

      Affiliations

    • Department of Hepatology, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo 105-8470, Japan
    • ,
  • Satoshi Saito

      Affiliations

    • Department of Hepatology, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo 105-8470, Japan
    • ,
  • Kenji Ikeda

      Affiliations

    • Department of Hepatology, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo 105-8470, Japan
    • ,
  • Mariko Kobayashi

      Affiliations

    • Research Institute for Hepatology, Toranomon Branch Hospital, Kawasaki, Japan
    • ,
  • Sachiyo Watahiki

      Affiliations

    • Research Institute for Hepatology, Toranomon Branch Hospital, Kawasaki, Japan
    • ,
  • Rie Mineta

      Affiliations

    • Research Institute for Hepatology, Toranomon Branch Hospital, Kawasaki, Japan
    • ,
  • Satomi Iwasaki

      Affiliations

    • Research Institute for Hepatology, Toranomon Branch Hospital, Kawasaki, Japan
    • ,
  • Hiromitsu Kumada

      Affiliations

    • Department of Hepatology, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo 105-8470, Japan

Received 22 April 2009 ,Revised 10 July 2009 ,Accepted 25 September 2009.

References 

  1. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958–965
  2. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–982
  3. Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, et al. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol. 2007;46:403–410
  4. Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346–355
  5. Lin C, Kwong AD, Perni RB. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. Infect Disord Drug Targets. 2006;6:3–16
  6. Reesink HW, Zeuzem S, Weegink CJ, Forestier N, Vliet AV, Rooij JVDWD , et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase 1b, placebo-controlled, randomized study. Gastroentrology. 2006;131:997–1002
  7. Sarrazin C, Kieffer TL, Bartels D, Hanzelka B, Muh U, Welker M, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroentrology. 2007;132:1767–1777
  8. Lawitz E, Rodriguez-Torres M, Muir AJ, Kieffer TL, McNair L, Khunvichai A, et al. Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients. J Hepatol. 2008;49:163–169
  9. McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med. 2009;360:1827–1838
  10. Hezode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med. 2009;360:1839–1850
  11. Ogata S, Florese RH, Nagano-Fujii M, Hidajat R, Deng L, Ku Y, et al. Identification of hepatitis C virus (HCV) subtype 1b strains that are highly, or only weakly, associated with hepatocellular carcinoma on the basis of the secondary structure of an amino-terminal portion of the HCV NS3 protein. J Clin Microbiol. 2003;41:2835–2841
  12. Kuntzen T, Timm J, Berical A, Lennon N, Berlin AM, Young SK, et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. Hepatology. 2008;48:1769–1778
  13. Bartels DJ, Zhou Y, Zhang EZ, Marcial M, Byrn RA, Pfeiffer T, et al. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3-4A protease inhibitors in treatment-naïve subjects. JID. 2008;198:800–807
  14. Cubero M, Esteban JI, Otero T, Sauleda S, Bes M, Esteban R, et al. Naturally occurring NS3-protease-inhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient. Virology. 2008;370:237–245
  15. Franco S, Parera M, Aparicio E, Clotet B, Martinez MA. Genetic and catalytic efficiency structure of an HCV protease quasispecies. Hepatology. 2007;45:899–910
  16. Foy E, Li K, Wang C, Surnpter R, Ikeda M, Lemon SM, et al. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science. 2003;300:1145–1148
  17. Johnson CL, Owen DM, Gale M. Functional and therapeutic analysis of hepatitis C virus NS3-4A protease control of antiviral immune defense. J Biol Chem. 2007;282:10792–10803
  18. Loo YM, Owen DM, Li K, Erickson AK, Johnson CL, Fish PM, et al. Viral and therapeutic control of IFN-β promoter stimulator 1 during hepatitis C virus infection. Proc Natl Acad Sci USA. 2006;103:6001–6006
  19. Liang Y, Ishida H, Lenz O, Lin TI, Nyanguile O, Simmen K, et al. Antiviral suppression vs restoration of RIG-I signaling by hepatitis C protease and polymerase inhibitors. Gastroentrology. 2008;135:1710–1718

PII: S1386-6532(09)00477-6

doi: 10.1016/j.jcv.2009.09.029

Journal of Clinical Virology
Volume 47, Issue 1 , Pages 76-78 , January 2010

Article Tools

* Image Usage & Resolution